"Pembrolizumab (P) in patients (Pts) with metastatic breast cancer (MBC" by Ajjai Shivaram Alva MD, Pam K. Mangat MS et al.
 

Pembrolizumab (P) in patients (Pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Publication/Presentation Date

5-31-2019

Disciplines

Medicine and Health Sciences

Department(s)

Department of Medicine, Hematology-Medical Oncology Division, Department of Medicine Faculty

Document Type

Presentation

This document is currently not available here.

Share

COinS